Jan 06, 2022 7:00am EST Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
Jan 04, 2022 7:00am EST Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
Jan 03, 2022 7:00am EST Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
Nov 12, 2021 8:00am EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
Oct 13, 2021 8:00am EDT Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
Oct 05, 2021 8:00am EDT Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City
Sep 22, 2021 4:05pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
Sep 13, 2021 8:00am EDT Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
Sep 07, 2021 8:00am EDT Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 12, 2021 8:00am EDT Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members
